.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Management of Myeloproliferative Neoplasms: A Focus on Polycythemia Vera and Myelofibrosis

EP. 1: Overview of Myeloproliferative Neoplasms

July 9th 2019

EP. 2: Differentiating Between Myeloproliferative Neoplasms

July 9th 2019

EP. 3: Diagnosing Polycythemia Vera

July 9th 2019

EP. 4: Suspecting Polycythemia Vera: Challenges in Diagnosis

July 9th 2019

EP. 5: Frontline Therapy for Polycythemia Vera

July 9th 2019

EP. 6: Treating Leukocytosis in Polycythemia Vera

July 9th 2019

EP. 7: Cytoreductive Therapy in Polycythemia Vera

July 9th 2019

EP. 8: Ruxolitinib for Treatment of Polycythemia Vera

July 9th 2019

EP. 9: RESPONSE-2 Trial: Ruxolitinib for PV

July 9th 2019

EP. 10: Interferon's Role in Treating Polycythemia Vera

July 9th 2019

EP. 11: Diagnosis and Risk Stratification in Myelofibrosis

July 9th 2019

EP. 12: Ruxolitinib's Role in Treating Myelofibrosis

July 9th 2019

EP. 13: COMFORT Ruxolitinib Studies for Myelofibrosis

July 9th 2019

EP. 14: Dosing of Ruxolitinib in PV and MF

July 9th 2019

EP. 15: Fedratinib in MF: JAKARTA2 and FREEDOM Trials

July 9th 2019

EP. 16: Emerging Agents Pacritinib and Momelotinib for MF

July 9th 2019

EP. 17: Other Pathways Studied for MF

July 9th 2019

EP. 18: Unmet Needs and Future Directions in Treating MPNs

July 9th 2019